Search

Your search keyword '"Lianidou, Evi"' showing total 779 results
Start Over Author "Lianidou, Evi"
779 results on '"Lianidou, Evi"'

5. Blood Transcriptomes of Anti-SARS-CoV-2 Antibody-Positive Healthy Individuals Who Experienced Asymptomatic Versus Clinical Infection.

Author

Sfikakis, Petros, Verrou, Kleio-Maria, Ampatziadis-Michailidis, Giannis, Tsitsilonis, Ourania, Paraskevis, Dimitrios, Kastritis, Efstathios, Lianidou, Evi, Moutsatsou, Paraskevi, Terpos, Evangelos, Trougakos, Ioannis, Chini, Vasiliki, Manoloukos, Menelaos, Moulos, Panagiotis, Pavlopoulos, Georgios, Kollias, George, Hatzis, Pantelis, and Dimopoulos, Meletios

Subjects
RNAseq, anti-SARS-CoV2 antibody, asympomatic, innate immunity, whole-blood, Adult, Antibodies, Viral, Asymptomatic Infections, COVID-19, Female, Gene Expression Profiling, Humans, Immunity, Innate, Male, RNA, Messenger, SARS-CoV-2, Sequence Analysis, RNA, Severity of Illness Index, Transcriptome
Abstract

The reasons behind the clinical variability of SARS-CoV-2 infection, ranging from asymptomatic infection to lethal disease, are still unclear. We performed genome-wide transcriptional whole-blood RNA sequencing, bioinformatics analysis and PCR validation to test the hypothesis that immune response-related gene signatures reflecting baseline may differ between healthy individuals, with an equally robust antibody response, who experienced an entirely asymptomatic (n=17) versus clinical SARS-CoV-2 infection (n=15) in the past months (mean of 14 weeks). Among 12.789 protein-coding genes analysed, we identified six and nine genes with significantly decreased or increased expression, respectively, in those with prior asymptomatic infection relatively to those with clinical infection. All six genes with decreased expression (IFIT3, IFI44L, RSAD2, FOLR3, PI3, ALOX15), are involved in innate immune response while the first two are interferon-induced proteins. Among genes with increased expression six are involved in immune response (GZMH, CLEC1B, CLEC12A), viral mRNA translation (GCAT), energy metabolism (CACNA2D2) and oxidative stress response (ENC1). Notably, 8/15 differentially expressed genes are regulated by interferons. Our results suggest that subtle differences at baseline expression of innate immunity-related genes may be associated with an asymptomatic disease course in SARS-CoV-2 infection. Whether a certain gene signature predicts, or not, those who will develop a more efficient immune response upon exposure to SARS-CoV-2, with implications for prioritization for vaccination, warrant further study.

Published
2021

8. Profiling Plasma Extracellular Vesicle Metabotypes and miRNAs: An Unobserved Clue for Predicting Relapse in Patients with Early-Stage NSCLC.

Author

Bafiti, Vivi, Thanou, Eleni, Ouzounis, Sotiris, Kotsakis, Athanasios, Georgoulias, Vasilis, Lianidou, Evi, Katsila, Theodora, and Markou, Athina

Abstract

Simple Summary: Prognosis, early detection, and relapse identification are jointly crucial factors for effective lung cancer treatment. Blood-based liquid biopsy, a non-invasive method, can provide solutions to the deadlocks in the management of this widespread cancer type by eliciting biomarkers. In this research, an integrated approach is developed, which combines the use of databases and experimental validation to find adequate biomarkers in non-small-cell lung cancer. The arising results, concerning miR-29a-3p in exosomes and lncRNA H19 in cfRNA, widen the horizons for identifying and exploiting promising biomarkers in non-small-cell lung cancer. Background and Objective: Lung cancer, the second most prevalent cancer globally, poses significant challenges in early detection and prognostic assessment. Despite advancements in targeted therapies and immunotherapy, the timely identification of relapse remains elusive. Blood-based liquid biopsy biomarkers, including circulating tumor cells (CTCs), cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), circulating-free RNAs (cfRNAs), and extracellular vesicles (EVs)/exosomes, offer promise for non-invasive monitoring. Methods: We employ a comprehensive approach integrating miRNA/lncRNA/metabolomic datasets, following a mixed-methods content analysis, to identify candidate biomarkers in NSCLC. NSCLC-associated miRNA/gene/lncRNA associations were linked to in silico-derived molecular pathways. Results: For data validation, mass spectrometry-based untargeted metabolomics of plasma EVs highlighted miRNA/lncRNA/metabotypes, linking "glycerophospholipid metabolism" to lncRNA H19 and "alanine, aspartate and glutamate metabolism" to miR-29a-3p. Prognostic significance was established for miR-29a-3p, showing lower expression in NSCLC patients with disease progression compared to stable disease (p = 0.004). Kaplan–Meier survival analysis indicated that patients with miR-29a-3p under-expression had significantly shorter overall survival (OS) (p = 0.038). Despite the expression of lncRNA H19 in plasma EVs being undetected, its expression in plasma cfRNAs correlated significantly with disease progression (p = 0.035). Conclusions: Herein, we showcase the potential of plasma EV-derived miR-29a-3p as a prognostic biomarker and underscore the intricate interplay of miRNAs, lncRNAs, and metabolites in NSCLC biology. Our findings offer new insights and avenues for further exploration, contributing to the ongoing quest for effective biomarkers in early-stage NSCLC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment.

Author

Ntzifa, Aliki, Marras, Theodoros, Kallergi, Galatea, Kotsakis, Athanasios, Georgoulias, Vasilis, and Lianidou, Evi

Subjects
GENE expression, DNA analysis, DNA methylation, LIQUID analysis, OSIMERTINIB
Abstract

Background: The heterogeneous and complex genetic landscape of NSCLC impacts the clinical outcomes of patients who will eventually develop resistance to osimertinib. Liquid biopsy (LB) analysis as a minimally invasive approach is a key step to efficiently identify resistance mechanisms and adjust to proper subsequent treatments. Materials and methods: In the present study, we combined plasma-cfDNA and CTC analysis from 30 NSCLC patients in samples collected before treatment and at the progression of disease (PD). We detected molecular alterations at the DNA mutation (EGFR, PIK3CA, KRAS G12C, BRAF V600E), DNA methylation (RASSF1A, BRMS1, FOXA1, SLFN1, SHISA3, RARβ,, WIF-1, RASSF10 and APC), gene expression (CK-19, CK-18, CK-8, AXL, TWIST-1, PD-L1, PIM-1, Vimentin, ALDH-1 , and B2M) and chromosomal level (HER2 and MET amplification) as possible resistance mechanisms and druggable targets. We also studied the expression of PD-L1 in single CTCs using immunofluorescence. Results: In some cases, T790M resistance EGFR mutation was detected at baseline in CTCs but not in the corresponding plasma cfDNA. PIK3CA mutations were detected only in plasma-cfDNA but not in corresponding CTCs. KRAS G12C and BRAF V600E mutations were not detected in the samples analyzed. MET amplification was detected in the CTCs of two patients before treatment whereas HER2 amplification was detected in the CTCs of three patients at baseline and in one patient at PD. DNA methylation analysis revealed low concordance between CTCs and cfDNA, indicating the complementary information obtained through parallel LB analysis. Results from gene expression analysis indicated high rates of vimentin-positive CTCs detected at all time points during osimertinib. Moreover, there was an increased number of NSCLC patients at PD harboring CTCs positive in PD-L1. AXL and PIM-1 expression detected in CTCs during treatment suggesting new possible therapeutic strategies. Discussion: Our results reveal that comprehensive liquid biopsy analysis can efficiently represent the heterogeneous molecular landscape and provide prominent information on subsequent treatments for NSCLC patients at PD since druggable molecular alterations were detected in CTCs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions

Author

Galani, Aikaterini, Aalizadeh, Reza, Kostakis, Marios, Markou, Athina, Alygizakis, Nikiforos, Lytras, Theodore, Adamopoulos, Panagiotis G., Peccia, Jordan, Thompson, David C., Kontou, Aikaterini, Karagiannidis, Apostolos, Lianidou, Evi S., Avgeris, Margaritis, Paraskevis, Dimitrios, Tsiodras, Sotirios, Scorilas, Andreas, Vasiliou, Vasilis, Dimopoulos, Meletios-Athanasios, and Thomaidis, Nikolaos S.

Published
2022
Full Text
View/download PDF

12. Molecular characterization of circulating tumor cells (CTCs) in sporadic medullary thyroid carcinoma (spMTC) patients

Author

Simeakis, George, primary, Lagopodi, Elina, additional, Saltiki, Katerina, additional, Romei, Cristina, additional, Ciampi, Raffaele, additional, Ramone, Teresa, additional, Constantoulakis, Pantelis, additional, Alevizaki, Maria, additional, Elisei, Rossella, additional, Markoy, Athina, additional, and Lianidou, Evi, additional

Published
2024
Full Text
View/download PDF

15. Liquid biopsy for the management of NSCLC patients under osimertinib treatment.

Author

Ntzifa, Aliki, Marras, Theodoros, Georgoulias, Vasilis, and Lianidou, Evi

Subjects
THERAPEUTIC use of antineoplastic agents, MEDICAL protocols, HETEROCYCLIC compounds, PROTEIN-tyrosine kinase inhibitors, BODY fluid examination, MINIMALLY invasive procedures, AMINES, LUNG cancer, GENETIC mutation, EPIDERMAL growth factor receptors, GENETIC testing
Abstract

Therapeutic management of NSCLC patients is quite challenging as they are mainly diagnosed at a late stage of disease, and they present a high heterogeneous molecular profile. Osimertinib changed the paradigm shift in treatment of EGFR mutant NSCLC patients achieving significantly better clinical outcomes. To date, osimertinib is successfully administered not only as first- or second-line treatment, but also as adjuvant treatment while its efficacy is currently investigated during neoadjuvant treatment or in stage III, unresectable EGFR mutant NSCLC patients. However, resistance to osimertinib may occur due to clonal evolution, under the pressure of the targeted therapy. The utilization of liquid biopsy as a minimally invasive tool provides insight into molecular heterogeneity of tumor clonal evolution and potent resistance mechanisms which may help to develop more suitable therapeutic approaches. Longitudinal monitoring of NSCLC patients through ctDNA or CTC analysis could reveal valuable information about clinical outcomes during osimertinib treatment. Therefore, several guidelines suggest that liquid biopsy in addition to tissue biopsy should be considered as a standard of care in the advanced NSCLC setting. This practice could significantly increase the number of NSCLC patients that will eventually benefit from targeted therapies, such as EGFR TKIs. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma

Author

Economopoulou, Panagiota, Kladi-Skandali, Athina, Strati, Areti, Koytsodontis, George, Kirodimos, Efthymios, Giotakis, Evangelos, Maragoudakis, Pavlos, Gagari, Eleni, Maratou, Eirini, Dimitriadis, George, Kotsantis, Ioannis, Vagia, Elena, Anastasiou, Maria, Gkotzamanidou, Maria, Kavourakis, George, Lianidou, Evi, and Psyrri, Amanda

Published
2020
Full Text
View/download PDF

19. Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC)

Author

Economopoulou, Panagiota, Koutsodontis, George, Strati, Areti, Kirodimos, Efthymios, Giotakis, Evangelos, Maragoudakis, Pavlos, Prikas, Constantine, Papadimitriou, Nikolaos, Perisanidis, Christos, Gagari, Eleni, Kotsantis, Ioannis, Vagia, Elena, Anastasiou, Maria, Gkotzamanidou, Maria, Kavourakis, George, Lianidou, Evi, and Psyrri, Amanda

Published
2019
Full Text
View/download PDF

21. Comprehensive Analysis of CXCR4, JUNB, and PD-L1 Expression in Circulating Tumor Cells (CTCs) from Prostate Cancer Patients.

Author

Roumeliotou, Argyro, Strati, Areti, Chamchougia, Foteini, Xagara, Anastasia, Tserpeli, Victoria, Smilkou, Stavroula, Lagopodi, Elina, Christopoulou, Athina, Kontopodis, Emmanouil, Drositis, Ioannis, Androulakis, Nikolaos, Georgoulias, Vassilis, Koinis, Filippos, Kotsakis, Athanasios, Lianidou, Evi, and Kallergi, Galatea

Subjects
PROSTATE cancer patients, CXCR4 receptors, PROGRAMMED death-ligand 1, OVERALL survival, BIOMARKERS
Abstract

CXCR4, JUNB and PD-L1 are implicated in cancer progression and metastasis. The current study investigated these biomarkers in CTCs isolated from metastatic prostate cancer (mPCa) patients at the RNA and protein levels. CTCs were isolated from 48 mPCa patients using the Ficoll density gradient and ISET system (17 out of 48). The (CK/PD-L1/CD45) and (CK/CXCR4/JUNB) phenotypes were identified using two triple immunofluorescence stainings followed by VyCAP platform analysis. Molecular analysis was conducted with an EpCAM-dependent method for 25/48 patients. CK-8, CK-18, CK-19, JUNB, CXCR4, PD-L1, and B2M (reference gene) were analyzed with RT-qPCR. The (CK+/PD-L1+/CD45-) and the (CK+/CXCR4+/JUNB+) were the most frequent phenotypes (61.1% and 62.5%, respectively). Furthermore, the (CK+/CXCR4+/JUNB-) phenotype was correlated with poorer progression-free survival [(PFS), HR: 2.5, p = 0.049], while the (CK+/PD-L1+/CD45-) phenotype was linked to decreased overall survival [(OS), HR: 262.7, p = 0.007]. Molecular analysis revealed that 76.0% of the samples were positive for CK-8,18, and 19, while 28.0% were positive for JUNB, 44.0% for CXCR4, and 48.0% for PD-L1. Conclusively, CXCR4, JUNB, and PD-L1 were highly expressed in CTCs from mPCa patients. The CXCR4 protein expression was associated with poorer PFS, while PD-L1 was correlated with decreased OS, providing new biomarkers with potential clinical relevance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. FIGURE 4 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

30. FIGURE 3 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

31. Supplementary Figure 2 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table 5 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Table 1 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure 4 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

35. Supplementary Table 2 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

36. Supplementary Materials and Methods from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

37. Supplementary Table 3 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

38. Supplementary Figure 5 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 3 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

40. Supplementary Table 4 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure 6 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

42. Data from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

43. FIGURE 2 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

44. Supplementary Figure 1 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

45. TABLE 1 from Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, primary, Papaxoinis, George, primary, Economopoulou, Panagiota, primary, Kotsantis, Ioannis, primary, Gkotzamanidou, Maria, primary, Anastasiou, Maria, primary, Pectasides, Dimitrios, primary, Kyrodimos, Efthymios, primary, Delides, Alexander, primary, Giotakis, Evangelos, primary, Papadimitriou, Nikolaos G., primary, Panayiotides, Ioannis G., primary, Perisanidis, Christos, primary, Fernandez, Aileen I., primary, Xirou, Vasiliki, primary, Poulios, Christos, primary, Gagari, Eleni, primary, Yaghoobi, Vesal, primary, Gavrielatou, Niki, primary, Shafi, Saba, primary, Aung, Thazin Nwe, primary, Kougioumtzopoulou, Andromachi, primary, Kouloulias, Vassilis, primary, Palialexis, Konstantinos, primary, Gkolfinopoulos, Stavros, primary, Strati, Areti, primary, Lianidou, Evi, primary, Fountzilas, George, primary, Rimm, David L., primary, Foukas, Periklis G., primary, and Psyrri, Amanda, primary

Published
2023
Full Text
View/download PDF

47. Phase II window study of olaparib alone or with cisplatin or durvalumab in operable Head and Neck Cancer

Author

Moutafi, Myrto, primary, Koliou, Georgia-Angeliki, additional, Papaxoinis, George, additional, Economopoulou, Panagiota, additional, Kotsantis, Ioannis, additional, Gkotzamanidou, Maria, additional, Anastasiou, Maria, additional, Pectasides, Dimitrios, additional, Kyrodimos, Efthymios, additional, Delides, Alexander, additional, Giotakis, Evangelos, additional, Papadimitriou, Nikolaos G., additional, Panayiotides, Ioannis G., additional, Perisanidis, Christos, additional, Fernandez, Aileen I., additional, Xirou, Vasiliki, additional, Poulios, Christos, additional, Gagari, Eleni, additional, Yaghoobi, Vesal, additional, Gavrielatou, Niki, additional, Shafi, Saba, additional, Aung, Thazin Nwe, additional, Kougioumtzopoulou, Andromachi, additional, Kouloulias, Vassilis, additional, Palialexis, Konstantinos, additional, Gkolfinopoulos, Stavros, additional, Strati, Areti, additional, Lianidou, Evi, additional, Fountzilas, George, additional, Rimm, David L., additional, Foukas, Periklis G., additional, and Psyrri, Amanda, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results